COX-2 selective nonsteroidal anti-inflammatory drugs: current status.

Simple item page
dc.contributor.authorMahajan, Aen_US
dc.contributor.authorSharma, Rashmien_US
dc.date.accessioned2005-03-02en_US
dc.date.accessioned2009-05-31T00:37:04Z
dc.date.available2005-03-02en_US
dc.date.available2009-05-31T00:37:04Z
dc.date.issued2005-03-02en_US
dc.description45 references.en_US
dc.description.abstractSince, their introduction, COX (cyclooxygenase enzyme)-2 specific inhibitors have become a rapidly growing segment of the prescription drug market. Researchers have recently focused on the potentially lethal side effects associated with their. FDA has banned the use of nimesulide (hepatotoxic) in pediatric patients and rofecoxib (cardiovascular complications) in both adults and children. COX-2 inhibitors may decrease vascular prostacyclin production and may tip the balance in favour of prothrombotic eicosanoids (thromboxane A2) and lead to increased cardiovascular thrombotic events. COX-2 inhibitors can also result into increase blood pressure, macular eruptions, urticaria, pseudoporphyria, erythema multiforme, oedema, worsening of heart failure, fatal allergic vasculitis and aggravation of doxorubicin-mediated cardiac injury. The COX-2 enzyme is also involved in the development of many organ systems, and its inhibition may lead to various congenital defects in neonates. It has been reported that COX-2 inhibitors also interfere with implantation, hence their use should be avoided in sexually active women at risk of pregnancy. However, presently the choice of COX-2 selective inhibitors for a particular patient should be based upon their relative efficacy, toxicity, concomitant drug use, concurrent disease states, hepatic and renal function and relative cost.en_US
dc.description.affiliationRheumatology Clinic, Postgraduate Department of Medicine, Government Medical College, Jammu.en_US
dc.identifier.citationMahajan A, Sharma R. COX-2 selective nonsteroidal anti-inflammatory drugs: current status. Journal of the Association of Physicians of India. 2005 Mar; 53(): 200-4en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/91462
dc.language.isoengen_US
dc.source.urihttps://www.japi.orgen_US
dc.subject.meshAdulten_US
dc.subject.meshAnti-Inflammatory Agents, Non-Steroidal --adverse effectsen_US
dc.subject.meshCardiovascular Diseases --chemically induceden_US
dc.subject.meshChilden_US
dc.subject.meshCyclooxygenase Inhibitors --adverse effectsen_US
dc.subject.meshHumansen_US
dc.subject.meshOsteoarthritis --drug therapyen_US
dc.subject.meshRandomized Controlled Trials as Topicen_US
dc.titleCOX-2 selective nonsteroidal anti-inflammatory drugs: current status.en_US
dc.typeJournal Articleen_US
dc.typeReviewen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Journal of the Association of Physicians of India